Sequencing of Agents for Castration-Resistant Prostate Cancer

In this review we will outline an approach to sequencing new therapies for metastatic castration-resistant prostate cancer (CRPC), with particular attention paid to the biology of CRPC.

Prostate Cancer

History of Prostate Cancer Linked With Risk for Melanoma

Leah Lawrence

News | December 04, 2013 | Melanoma, Prostate Cancer

By Leah Lawrence

Men with a history of prostate cancer may be at increased risk for melanoma, according to data taken from two large cohort studies.

Anxiety Linked to Prostate Biopsies

Anna Azvolinsky, PhD

News | November 29, 2013 | Prostate Cancer, Genitourinary Cancers

By Anna Azvolinsky, PhD

The results of a recently published study on the psychological impact of prostate cancer biopsies show that men who have post-biopsy symptoms have increased anxiety, even if they received a negative diagnosis.

Circling Back: PSA Screening for Colorectal Cancer Patients

Ayal A. Aizer, MD, MHS

November 24, 2013 | Oncology Journal, Colorectal Cancer, Gastrointestinal Cancer, Genitourinary Cancers, PSA Screening, Prostate Cancer, Screening

By Ayal A. Aizer, MD, MHS

In this podcast, we discuss whether all male colorectal cancer patients over the age of 60 should be screened for prostate cancer.

Sequencing of Agents for Castration-Resistant Prostate Cancer

Michael Hurwitz, MD, PhD

Daniel P. Petrylak, MD

Review Article | November 15, 2013 | Prostate Cancer, Genitourinary Cancers, Oncology Journal

By Michael Hurwitz, MD, PhD and Daniel P. Petrylak, MD

In this review we will outline an approach to sequencing new therapies for metastatic castration-resistant prostate cancer (CRPC), with particular attention paid to the biology of CRPC.

Sequencing Medical Therapy in Prostate Cancer: Not as Easy as 1-2-3

Elizabeth R. Kessler, MD

Thomas W. Flaig, MD

November 15, 2013 | Prostate Cancer, Genitourinary Cancers, Oncology Journal

By Elizabeth R. Kessler, MD and Thomas W. Flaig, MD

With the emergence of several new agents for the treatment of advanced prostate cancer, new questions have arisen regarding the optimal sequence or combination of these agents. As we await the results of ongoing and planned clinical trials to answer some of these questions directly, the decision-making process will rely heavily on considerations of side effects and patient characteristics.

The Success of Therapies for Metastatic CRPC Continues

Neal D. Shore, MD, FACS

November 15, 2013 | Prostate Cancer, Genitourinary Cancers, Oncology Journal

By Neal D. Shore, MD, FACS

I have read multiple overviews of the current management of castration-resistant prostate cancer (CRPC). These articles have very adeptly summarized the key trials leading to a multitude of US Food and Drug Administration (FDA) approvals of new agents for men with CRPC.

Death From Prostate Cancer Linked to Weight at Diagnosis

Anna Azvolinsky, PhD

News | November 09, 2013 | Prostate Cancer, Genitourinary Cancers

By Anna Azvolinsky, PhD

A recent study shows that men who were overweight or obese at the time of their prostate cancer diagnosis were more likely to die from their disease compared with their healthy weight counterparts.

Pages

Videos
Podcasts

ASCO: Screening for PSA in Prostate Cancer
Nancy A. Dawson, MD
August 05, 2011 | ASCO 2011, PSA Screening, Prostate Cancer
By Nancy A. Dawson, MD
Nancy Dawson, MD discusses PSA dynamics: the significance of PSA levels and PSA doubling time—the marker which currently provides the most information—and their usefulness in predicting metastatic disease and in counseling patients on their prognosis.

Circling Back: PSA Screening for Colorectal Cancer Patients
Ayal A. Aizer, MD, MHS
November 24, 2013 | Oncology Journal, Colorectal Cancer, Gastrointestinal Cancer, Genitourinary Cancers, PSA Screening, Prostate Cancer, Screening
By Ayal A. Aizer, MD, MHS
In this podcast, we discuss whether all male colorectal cancer patients over the age of 60 should be screened for prostate cancer.
ASCO: Preview of the Prostate Cancer Sessions
Robert Dreicer, MD
May 30, 2013 | Prostate Cancer, ASCO 2013, ASCO 2013 Prostate Cancer, Genitourinary Cancers
By Robert Dreicer, MD
Ahead of the 2013 ASCO meeting we highlight some of this year's prostate cancer sessions, many of which focus on how best to use the new agents that have been approved recently, as well as looking into new drugs and combinations presented from early trials.
ASCO GU: Early Treatment and Active Surveillance of Prostate Cancer Patients
Mack Roach, MD
Hans T. Chung, MD
February 13, 2013 | Genitourinary Cancers, Prostate Cancer
By Mack Roach, MD and Hans T. Chung, MD
Ahead of the ASCO GU meeting, we spoke with two symposium committee members, Dr. Mack Roach, of the University of California, San Francisco, and Dr. Hans T. Chung, of the University of Toronto, about early treatment and surveillance of prostate cancer patients.
Prostate Cancer Controversies: PSA Screening; Treatment or Observation for Early Disease
Ian Thompson, MD
August 14, 2012 | Prostate Cancer, Genitourinary Cancers, PSA Screening, Screening
By Ian Thompson, MD
We discuss the current controversies in prostate cancer—PSA screening and approaches to initial treatment for men diagnosed with the disease.

Prostate Cancer

Sequencing of Agents for Castration-Resistant Prostate Cancer

Topics

Prostate Cancer

Pages

Oncology Current Issue

SearchMedica Rx

Register Today — It's Free!

UBM Medica Network

About UBM Medica

Prostate Cancer

Sequencing of Agents for Castration-Resistant Prostate Cancer

Topics

Prostate Cancer

Pages

Already Registered? Login Now:

Register Today - It's Free!

Oncology Current Issue

SearchMedica Rx

Register Today — It's Free!

UBM Medica Network

About UBM Medica

Find Us On...